Navigation Links
Masimo Reports First Quarter 2013 Financial Results
Date:5/2/2013

IRVINE, Calif., May 2, 2013 /PRNewswire/ -- Masimo (NASDAQ: MASI) today announced its financial results for the first quarter ended March 30, 2013.

Masimo's total first quarter revenue, including royalties, rose 14% to $135.9 million, compared to $119.2 million for the first quarter of 2012.  First quarter 2013 product revenue rose 15% to $128.6 million, compared to $112.2 million for the first quarter of 2012.  The company's worldwide direct product revenue grew 13% in the first quarter of 2013 and represented 84% of product revenue.  OEM sales, which accounted for 16% of product revenue, rose 26% compared to the same period in 2012.  Revenue from sales of Masimo rainbow products rose 24% to $10.5 million in the first quarter, compared to $8.5 million for the first quarter of 2012.  

Net income for the first quarter of 2013 was $16.4 million, or $0.28 per diluted share, compared to net income of $15.8 million, or $0.27 per diluted share, in the first quarter of 2012.  First quarter 2013 earnings per share were reduced by approximately $0.03 due to non-operating expenses primarily related to realized and unrealized net losses on foreign currency denominated transactions due to the strengthening of the U.S. dollar against the Japanese yen.

During the first quarter, the company shipped approximately 39,500 Masimo SET pulse oximetry and Masimo rainbow SET Pulse CO-Oximetry units, excluding handheld units, up 19% compared to approximately 33,300 in the same prior-year period.  Masimo estimates its worldwide installed base as of March 30, 2013 to be 1,117,000 units, up 11% from 1,005,000 units as of March 31, 2012.Joe Kiani, Chairman and Chief Executive Officer of Masimo, said, "Masimo is off to a solid start in 2013, with product revenue up 15%, fueled by a 14% rise in our core SET Pulse Oxime
'/>"/>

SOURCE Masimo Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Essential Medical Dismisses Patent Case against Masimo and Cercacor
2. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
3. Novation Inks Supplier Contract Category Agreement for Masimo SET® pulse oximetry and rainbow® SET Pulse CO-Oximetry™
4. Masimo to Present at William Blair & Company 32nd Annual Growth Stock Conference
5. Masimo CEO Joe Kiani Named Ernst & Young Entrepreneur of the Year
6. Masimo Signs Pronto-7™ Distribution Deal with Henry Schein
7. Masimo Deploys Kinaxis RapidResponse for Global Demand and Supply Balancing
8. Masimo to Report Second Quarter 2012 Financial Results after Market Close on August 1
9. Masimo Signs Pulse Oximetry Distribution Deal with MWI Veterinary Supply
10. Masimo Reports Second Quarter 2012 Financial Results
11. Masimo Enters Noninvasive Multigas Monitoring, including Capnography, with Acquisition of PHASEIN
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... According to the new ... (Equipment, Reagent, Primer, Probe, Custom Oligos), End-User (Research, ... Synthesis, NGS, DNA, RNAi) - Global Forecast to ... Market is expected to reach $1,712.1 Million by ... a CAGR of 9.8% from 2014 to 2019.. ...
(Date:8/29/2014)... , Aug. 29, 2014 Research ... "Global Multiple Sclerosis Drugs Market 2014-2018" report ... a chronic, inflammatory medical condition that results in demyelination, ... because of an abnormal response by the immune system, ... It is a potentially debilitating disease in which the ...
(Date:8/29/2014)... and MENLO PARK, Calif. ... Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" "the Company") today ... financial statements.  The Company recently changed its fiscal year ... application to list its common stock on a national ... DelMar,s financial statements as filed with the United States ...
Breaking Medicine Technology:Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 4DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 5
... Jan. 5, 2011 Although smoking is an expensive habit, ... quit smoking can seem like expensive purchases as well.  The ... try to do it "cold turkey" – the most popular ... to relapse.   The use of store brand ...
... Avaxia Biologics, Inc., a privately-held biotech company developing ... to the gastrointestinal tract, announced today that it ... of inflammatory bowel disease (IBD). Avaxia,s orally administered ... three different animal models and showed superior efficacy ...
Cached Medicine Technology:Resolved to Quit Smoking This Year? 2Resolved to Quit Smoking This Year? 3Avaxia Biologics, Inc. to Present Key Pre-Clinical Inflammatory Bowel Disease Remission Data at Biotech Showcase 2011 2
(Date:9/1/2014)... Developers of FCPX 3rd Party Products have announced ... Plugin from Pixel Film Studios. , “ProWorld has pushed the ... users now have the ability to create a 3D world ... Pixel Film Studios. “Blurring the line between professional and armature, ... turn a 2D HDRI image or Skybox Texture into a ...
(Date:9/1/2014)... 2014 Psychogenic Non-epileptic Seizures (PNES), also ... disorder that can have devastating effects on those who ... seizures however, they are not produced by electrical anomalies ... It is estimated that the numbers of persons suffering ... sclerosis. , Dr. Lorna Myers, Director of ...
(Date:8/31/2014)... An analysis of 32 studies compiled by ... link between lower levels of Vitamin D and a ... August 2014 issue of American Journal of Public ... Vitamin D found in blood. , Researchers found ... than 9 nanograms/milliliter (ng/mL) were twice as likely to ...
(Date:8/31/2014)... 2014 MedixSafe has become very popular ... and narcotics lockers . Electronic Security Specialists ... for distribution worldwide. “We have now shipped multiple orders ... MedixSafe Sales Manager , MedixSafe is a division of ... network cabling company with over 30 years in the ...
(Date:8/31/2014)... 2014 Just in time for Washington’s Indian ... wild, sustainable Alaska Salmon, award winning chowder and ... Duke's Green Lake location , Sunday, September 28, 2014 from ... several ethnic salmon BBQ culinary delights. Live music will add ... Hawaii, Puerto Rico and Mexico will be featured. “There ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios Released a New Tutorial Entitled ProWorld Lesson Exclusively for Final Cut Pro X 2Health News:The Northeast Regional Epilepsy Group (NEREG) Offers First Conference on Psychogenic Non-epileptic Seizures (PNES) on September 20, 2014 in New Jersey 2Health News:NutriGold Highlights New Study on the Importance of Vitamin D to Our Life Span 2Health News:NutriGold Highlights New Study on the Importance of Vitamin D to Our Life Span 3Health News:NutriGold Highlights New Study on the Importance of Vitamin D to Our Life Span 4Health News:Memphis-based Electronic Security Specialists Now Offers MedixSafe Narcotics Cabinets Internationally 2Health News:Memphis-based Electronic Security Specialists Now Offers MedixSafe Narcotics Cabinets Internationally 3Health News:Seattle Seafood Restaurant Duke's Chowder House on Green Lake Will Celebrate The Long Anticipated Indian Summer With First Annual Sizzling BBQ Salmon Tasting Event. 2
... took place even in prehistoric times. , , FRIDAY, June 13 ... based on the findings of a prehistoric mass grave in ... evidence from 34 skeletons dating back to around 5000 B.C. ... over the need for female companionship. , While adult ...
... June 13 EntreMed, Inc.,(Nasdaq: ENMD ... the treatment of cancer and inflammatory diseases,announced ... Chief Executive Officer,will present a Company overview ... Organization 2008 Annual International Convention,being held June ...
... trachomatis, the most ... Calif., June 13 Roche announced today that,its new ... Mark,certification, allowing it to be sold for clinical use ... target approach to help ensure,reliability of test results even ...
... terrorist attacks of September 11, 2001, had lasting psychological ... World Trade Center Health Registry, show that one in ... (PTSD) two to three years after the attacks. The ... three times the usual rate in the years following ...
... for Prevention, Mental,Health and Low-Income Programs, Boosted Quality ... Today a minority of,the U.S. Senate blocked critical ... million Americans who depend on it. The Medicare,Improvements ... improved,Medicare,s prevention, mental health, and low-income programs and,instituted ...
... Synovics,Pharmaceuticals, Inc., (OTC Bulletin Board: SYVC) a ... 2008, it formalized,a strategic partnership with Maneesh Pharmaceuticals, ... ("JV"). The JV between the,companies is intended to ... have access,to assets of Maneesh including personnel, drug ...
Cached Medicine News:Health News:Pursuit of Females Dates Way, Way Back 2Health News:EntreMed to Present at the BIO 2008 Annual International Convention 2Health News:New Roche Chlamydia Test Approved for Use in European Union 2Health News:New Roche Chlamydia Test Approved for Use in European Union 3Health News:1 in 8 Lower Manhattan residents had signs of PTSD 2 to 3 years after 9/11 2Health News:AARP NY Key Vote News Alert: AARP Dismayed by Senate Vote to Block Medicare Improvement Bill 2Health News:AARP NY Key Vote News Alert: AARP Dismayed by Senate Vote to Block Medicare Improvement Bill 3Health News:Synovics Pharmaceuticals forms a Strategic Joint Venture with Maneesh Pharmaceuticals 2Health News:Synovics Pharmaceuticals forms a Strategic Joint Venture with Maneesh Pharmaceuticals 3Health News:Synovics Pharmaceuticals forms a Strategic Joint Venture with Maneesh Pharmaceuticals 4Health News:Synovics Pharmaceuticals forms a Strategic Joint Venture with Maneesh Pharmaceuticals 5Health News:Synovics Pharmaceuticals forms a Strategic Joint Venture with Maneesh Pharmaceuticals 6
Binocular indirect ophthalmic lenses. Median field diagnosis & treatment....
Binocular indirect ophthalmic lenses. Ultra-High resolutions viewing of posterior pole....
... Volk's super series ... lenses. General retinal ... unprecedented fundus diagnostic ... maximum potential field ...
Volk indirect lenses. Standard BIO examinations....
Medicine Products: